Advanced Lung Preservation Solution for Organ Transplant

Publication ID: 24-11856944_0006_PTD

Published: October 26, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Advanced Lung Preservation Solution for Organ Transplant,” Published Technical Disclosure No. 24-11856944_0006_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856944_0006_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,944.

Background and Problem Solved

Current organ preservation techniques, such as those described in the original patent, have limitations including oxidative stress, inefficient perfusion, and inadequate oxygenation. This invention addresses these limitations by introducing novel components and adjustments to the perfusion solution and system, enabling more efficient and effective ex-vivo lung perfusion.

Novelty and Inventive Step

The invention's novelty lies in the combination of novel antioxidant components, real-time perfusion liquid adjustments, modified colloid components, and advanced gas exchange modules, which collectively provide a significant improvement over the original patent. The inventive step is the integration of these components to create a more efficient, effective, and viable ex-vivo lung perfusion system.

Alternative Embodiments and Variations

Alternative embodiments may include variations in the antioxidant component, colloid composition, or gas exchange module design. Additionally, the system could be adapted for perfusion of other organs, such as the heart or liver, or integrated with other organ preservation technologies.

Potential Commercial Applications and Market

The enhanced organ care solution has significant commercial potential in the organ transplantation market, addressing the need for improved lung preservation and transplantation outcomes. The invention could be marketed to organ procurement organizations, transplantation centers, and pharmaceutical companies, with potential applications in human transplantation and potentially in veterinary medicine.

CPC Classifications

Section	Class	Group
A	A01	A01N1/0226
A	A01	A01N1/0247

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Organ preservation and ex-vivo perfusion technologies, specifically focusing on lung preservation techniques with expertise in biochemical composition, perfusion solutions, and organ maintenance systems

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or medical researcher with advanced degrees in bioengineering, biochemistry, or transplant medicine, possessing knowledge of organ preservation techniques, perfusion solution chemistry, and medical device design

Obviousness Rationale

A PHOSITA would recognize that the PTD's proposed variations represent incremental improvements to the existing organ perfusion methodology disclosed in the source patent, utilizing known techniques and modifications that would be predictable to an expert in organ preservation technologies. The proposed antioxidant components, real-time perfusion adjustments, and modified colloid systems represent logical extensions of the existing perfusion solution design. These variations demonstrate standard engineering problem-solving approaches within the field of ex-vivo organ preservation.

Obvious Combinations & Variations

Source Patent Element

Perfusion liquid with specific nutrient and colloid composition

PTD Variation

Modified colloid component with improved viscosity and oncotic pressure properties

Obviousness Reasoning

A PHOSITA would recognize that adjusting colloid compositions to optimize perfusion characteristics is a predictable design variation using known biochemical engineering techniques

Source Patent Element

Static perfusion solution composition

PTD Variation

Real-time perfusion liquid adjustments based on continuous lung function monitoring

Obviousness Reasoning

Implementing dynamic monitoring and adjustment of perfusion parameters represents a standard technological progression in medical device design, utilizing known sensor and feedback control technologies

Source Patent Element

Basic organ preservation solution

PTD Variation

Novel antioxidant component to reduce oxidative stress during ex-vivo preservation

Obviousness Reasoning

Incorporating antioxidant mechanisms to mitigate cellular damage is a well-established approach in organ preservation research, representing a predictable solution to known preservation challenges

Source Patent Element

Standard lung perfusion methodology

PTD Variation

Advanced gas exchange module for improved oxygenation and CO2 removal

Obviousness Reasoning

Enhancing gas exchange capabilities through modular design improvements is a routine engineering approach in medical device development, representing an obvious optimization strategy

Source Patent Element

Basic lung viability assessment

PTD Variation

Novel biomarker panel to evaluate lung function and predict transplantation outcomes

Obviousness Reasoning

Developing more sophisticated diagnostic techniques using biomarker analysis is a standard scientific approach to improving medical assessment technologies

35 U.S.C. § 103 Summary: Based on the comprehensive teachings of US Patent 11856944 and the disclosed variations in the Published Technical Disclosure, a person having ordinary skill in the art would find the proposed lung perfusion system modifications to be obvious extensions of existing organ preservation technologies. The incremental improvements represent predictable variations that would be readily conceived by a skilled practitioner without requiring inventive insight beyond the ordinary capabilities of those skilled in organ preservation and biomedical engineering.

Original Patent Information

Patent Number	US 11,856,944
Title	Organ care solution for ex-vivo machine perfusion of donor lungs
Assignee(s)	TRANSMEDICS, INC.